Dirk Sibbing

Summary

Publications

  1. doi request reprint Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    Dirk Sibbing
    Deutsches Herzzentrum Munchen, Lazarettstrasse 36, 80636 München, Germany
    Circulation 121:512-8. 2010
  2. ncbi request reprint A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
    Nicolas von Beckerath
    Deutches Herzzentrum, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 28:1814-9. 2007
  3. doi request reprint Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Klinik für Herz und Kreislauferkrankungen Lazarettstr 3680636 Munich, Germany
    Thromb Haemost 104:626-32. 2010
  4. doi request reprint A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients
    Niels Straub
    PD Dr med Dirk Sibbing, I Medizinische Klinik und Poliklinik, Ludwig Maximilians Universitat Munchen, Marchioninistr 15, 81377 Munchen, Germany, Tel 49 89 7095 2371, Fax 49 89 7095 8870, E mail
    Thromb Haemost 111:290-9. 2014
  5. doi request reprint Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Lazarettstrasse36, Munich, Germany
    J Am Coll Cardiol 60:369-77. 2012
  6. doi request reprint Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Lazarettstrasse 36, 80636 München, Germany
    Thromb Haemost 103:151-9. 2010
  7. ncbi request reprint Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Thromb Haemost 101:714-9. 2009
  8. doi request reprint Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    Dirk Sibbing
    Deutsches Herzzentrum and Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Am Coll Cardiol 53:849-56. 2009
  9. doi request reprint A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Am Coll Cardiol 55:558-65. 2010
  10. doi request reprint High platelet reactivity and clinical outcome - fact and fiction
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Lazarettstrasse 36, 80636 München, Germany
    Thromb Haemost 106:191-202. 2011

Collaborators

Detail Information

Publications41

  1. doi request reprint Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    Dirk Sibbing
    Deutsches Herzzentrum Munchen, Lazarettstrasse 36, 80636 München, Germany
    Circulation 121:512-8. 2010
    ..The aim of this study was to assess the impact of CYP2C19*17 on ADP-induced platelet aggregation, the risk of bleeding, and stent thrombosis in clopidogrel-treated patients undergoing percutaneous coronary intervention...
  2. ncbi request reprint A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
    Nicolas von Beckerath
    Deutches Herzzentrum, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 28:1814-9. 2007
    ..We sought to test whether an increase in the clopidogrel maintenance dose results in increased inhibition of platelet aggregation...
  3. doi request reprint Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Klinik für Herz und Kreislauferkrankungen Lazarettstr 3680636 Munich, Germany
    Thromb Haemost 104:626-32. 2010
    ..The higher mortality is probably due to confounding as patients on PPIs had a higher risk profile at baseline...
  4. doi request reprint A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients
    Niels Straub
    PD Dr med Dirk Sibbing, I Medizinische Klinik und Poliklinik, Ludwig Maximilians Universitat Munchen, Marchioninistr 15, 81377 Munchen, Germany, Tel 49 89 7095 2371, Fax 49 89 7095 8870, E mail
    Thromb Haemost 111:290-9. 2014
    ..In this model-based analysis, a PFT-guided therapy may have fewer adverse outcomes than general treatment with clopidogrel and may be more cost-effective than prasugrel or ticagrelor treatment in ACS patients undergoing PCI...
  5. doi request reprint Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Lazarettstrasse36, Munich, Germany
    J Am Coll Cardiol 60:369-77. 2012
    ....
  6. doi request reprint Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Lazarettstrasse 36, 80636 München, Germany
    Thromb Haemost 103:151-9. 2010
    ..In the majority of clopidogrel low responders suffering ST, the ischaemic event occurs early in the course after the procedure...
  7. ncbi request reprint Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Thromb Haemost 101:714-9. 2009
    ..Specifically designed and randomized clinical studies are needed to define the impact of concomitant PPI treatment on adverse events after percutaneous coronary intervention...
  8. doi request reprint Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    Dirk Sibbing
    Deutsches Herzzentrum and Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Am Coll Cardiol 53:849-56. 2009
    ..The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)...
  9. doi request reprint A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Am Coll Cardiol 55:558-65. 2010
    ..The goal of this study was to assess whether a platelet rebound exists and whether it can be attenuated by clopidogrel tapering...
  10. doi request reprint High platelet reactivity and clinical outcome - fact and fiction
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Lazarettstrasse 36, 80636 München, Germany
    Thromb Haemost 106:191-202. 2011
    ..This review aims to summarise available facts and fiction in relation to platelet function testing and reactivity with a particular focus on P2Y12 receptor inhibition in patients undergoing coronary stent placement...
  11. doi request reprint Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
    D Sibbing
    Deutsches Herzzentrum München and I Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Thromb Haemost 8:250-6. 2010
    ..In patients undergoing percutaneous coronary intervention (PCI), a link between bleeding and excess mortality has been demonstrated. A potential association of platelet response to clopidogrel and bleeding has not been well established yet...
  12. doi request reprint Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Lazarettstrasse, Munich, Germany
    Eur Heart J 31:1205-11. 2010
    ..The aim of this study was to investigate the impact of phenprocoumon on the antiplatelet effects of clopidogrel in patients with coronary artery disease...
  13. doi request reprint Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Thromb Haemost 99:121-6. 2008
    ..71; P < 0.0001). The results of MEA, a fast and standardized method to assess the platelet response to ADP prior to and after clopidogrel treatment, correlate well with LTA...
  14. ncbi request reprint Role of platelet function testing in clinical practice: current concepts and future perspectives
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Germany
    Curr Drug Targets 12:1836-47. 2011
    ....
  15. ncbi request reprint Patent foramen ovale with a riding vermicular thrombus causing paradoxical and massive pulmonary embolism
    Dirk Sibbing
    Department of Cardiology, Deutsches Herzzentrum München and 1 Medizinische Klinik, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 27:2724. 2006
  16. doi request reprint Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
    D Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Thromb Haemost 8:1685-93. 2010
    ..Currently, the isolated and interactive impacts of both variants on the antiplatelet effects of chronic clopidogrel therapy are unknown...
  17. doi request reprint No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Lazarettstrasse 36, Munich, Germany
    Eur Heart J 32:1605-13. 2011
    ..The aim of this study was to assess the impact of the PON1 Q192R genotype in parallel to that of CYP2C19*2 on the antiplatelet effect of clopidogrel and the risk of ST in clopidogrel-treated patients...
  18. doi request reprint Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment
    Isabell Bernlochner
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Thromb Haemost 104:1193-200. 2010
    ..Whether a direct relation between platelets and inflammation exists, as well as the clinical impact of our results, warrants further investigations...
  19. doi request reprint Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting
    Isabell Bernlochner
    Deutsches Herzzentrum, Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Thromb Haemost 109:517-24. 2013
    ..However, prasugrel response variability was detected, being more pronounced on prasugrel MD vs. LD treatment. The clinical impact of these findings warrants further investigation...
  20. doi request reprint Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 29:1504-9. 2008
    ....
  21. doi request reprint Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents
    Stefanie Schulz
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    Am Heart J 160:355-61. 2010
    ..The aim of this study was to assess the impact of platelet response to clopidogrel on the risk of restenosis after drug-eluting stenting (DES)...
  22. doi request reprint No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting
    Juliane Jaitner
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Circ Cardiovasc Interv 5:82-8, S1-2. 2012
    ....
  23. doi request reprint Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
    Klaus A Tiroch
    Deutsches Herzzentrum Munchen, Rechts der Isar, Technische Universitat, Germany
    Am Heart J 160:506-12. 2010
    ..Reduced-function alleles have been associated with an increase in cardiovascular events...
  24. ncbi request reprint Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention
    Gabriele Busch
    Deutsches Herzzentrum, Lazarettstrasse 36, 80636 Munich, Germany
    Thromb Haemost 101:340-4. 2009
    ..In conclusion, our data suggest that bivalirudin may reduce platelet and monocyte activation in patients undergoing elective PCI. Thereby, bivalirudin might reduce periinterventional thrombotic complications...
  25. doi request reprint Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry
    Nicolas von Beckerath
    Deutsches Herzzentrum, 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood Coagul Fibrinolysis 21:46-52. 2010
    ....
  26. doi request reprint Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
    Dirk Sibbing
    Department of Cardiology, Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 30:916-22. 2009
    ..The aim of this study was to assess the impact of the CYP2C19 681G>A loss-of-function polymorphism on ST following PCI performed after pre-treatment with clopidogrel...
  27. doi request reprint Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    Nikolaus Sarafoff
    Klinikum der Ludwig Maximilians Universität München, Medizinische Klinik und Poliklinik I, Munich, Germany
    J Am Coll Cardiol 61:2060-6. 2013
    ..This study sought to evaluate whether prasugrel may serve as an alternative to clopidogrel in patients with triple therapy...
  28. doi request reprint Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients
    Juliane Jaitner
    Deutsches Herzzentrum München and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munchen, Munich, Germany
    Thromb Haemost 105:107-12. 2011
    ..In conclusion, the HPR phenotype is stable over time in the majority of clopidogrel-treated patients. Comparative assessment of phenotype stability across available platelet function assays warrants further investigation...
  29. doi request reprint Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Munich, Germany
    Am Heart J 161:605-10. 2011
    ..The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement...
  30. doi request reprint A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel
    Isabell Bernlochner
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Platelets 24:15-25. 2013
    ..81, p < 0.001), which was greater following a prasugrel LD...
  31. ncbi request reprint Platelet function in clopidogrel-treated patients with acute coronary syndrome
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
    Blood Coagul Fibrinolysis 18:335-9. 2007
    ..0001). Patients with ACS continue to exhibit increased platelet activation after pretreatment with 600 mg clopidogrel. This finding supports the need for additional platelet function inhibition during PCI in patients with ACS...
  32. ncbi request reprint Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Am J Cardiol 100:203-5. 2007
    ..005). In conclusion, administration of a single high loading dose of clopidogrel 600 mg does not inhibit platelet aggregation in overweight patients to the same extent as in normal-weight patients...
  33. doi request reprint The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders
    Isabell Bernlochner
    Deutsches Herzzentrum Munchen, Lazarettstrasse 36, Munich, Germany
    Expert Rev Cardiovasc Ther 9:999-1014. 2011
    ..This article reviews the impact of antiplatelet drug responsiveness on clinical outcomes with a focus on P2Y(12) receptor inhibition as well as on current and future concepts for personalized antiplatelet strategies...
  34. doi request reprint Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor
    Martin Orban
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Technische Universitat Munchen, Munich, Germany
    Platelets 23:395-8. 2012
    ....
  35. ncbi request reprint Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood Coagul Fibrinolysis 16:511-5. 2005
    ..The PAI-1 4G/5G polymorphism has no impact on the amount of myocardial salvage achieved by reperfusion with stenting or thrombolysis in patients with AMI...
  36. ncbi request reprint Platelet hyperreactivity and stent thrombosis in patients undergoing coronary stenting
    Katharina Mayer
    Deutsches Herzzentrum Munchen, Klinik an der Technischen Universität München, Lazarettstraβe 36, D 80636 München, Germany
    Curr Vasc Pharmacol 10:597-605. 2012
    ..This review paper aims to summarize the important facts in relation to ST and antiplatelet therapy with a particular focus on P2Y12 receptor inhibition and its ex vivo assessment in patients undergoing coronary stent placement...
  37. doi request reprint A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction
    Melchior Seyfarth
    Deutsches Herzzentrum Munchen, Technische Universitat, Munich, Germany
    J Am Coll Cardiol 52:1584-8. 2008
    ..The aim of this study was to test whether the left ventricular assist device (LVAD) Impella LP2.5 (Abiomed Europe GmbH, Aachen, Germany) provides superior hemodynamic support compared with the intra-aortic balloon pump (IABP)...
  38. doi request reprint Platelet function testing in patients with acute coronary syndrome
    Martin Orban
    Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig Maximilians Universitat Munchen, Campus Grosshadern, Marchioninistr 15, 81377 Munich, Germany
    J Cardiovasc Transl Res 6:371-7. 2013
    ....
  39. ncbi request reprint Clinical use of clopidogrel
    Nikolaus Sarafoff
    Deutsches Herzzentrum, Technische Universität Munich, Germany
    Curr Pharm Des 18:5224-39. 2012
    ....
  40. doi request reprint Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy
    Dirk Sibbing
    Deutsches Herzzentrum Munchen, Munich, Germany
    Eur Heart J 32:1121-33. 2011
    ..Cardiac-specific deletion of Txnrd2 in mice results in dilated cardiomyopathy (DCM). The aim of this study was to investigate whether TXNRD2 mutations explain a fraction of monogenic DCM cases...
  41. ncbi request reprint Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness
    Nicolas von Beckerath
    Thromb Haemost 95:910-1. 2006